CALGARY, Alberta, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announced that Dr. Eldon Smith has stepped down from the Board of Directors, effective today.

“We would like to thank Eldon for his many years of service and wish him all the best,” said Donald McCaffrey, President and CEO of the Company. “We appreciate Eldon’s many contributions and guidance over the years, helping to greatly advance our programs, and are excited to continue the development of apabetalone. The major opportunities in front of us are numerous. We continue to aggressively pursue a multi-point strategy that includes potential breakthrough status filings with regulators and strategic partnerships for multiple indications. All this on the heels of recent significant BETonMACE results which produced very encouraging data, particularly in the chronic kidney disease and cognitive decline patient groups. In addition, we uncovered positive surprise findings when apabetalone is combined with the new generation of diabetes drugs – SGLT2 inhibitors – in this CVD patient population. We look forward to providing further updates in the near future and look forward to a very prosperous 2020.”